Image via Wikipedia
Thursday, 13 August 2009
Cannabis Science, Inc. (OTCBB: CBIS) an emerging pharmaceutical cannabis company is pleased to announce that it has completed its review of the FDA licencing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials. The Company has determined it will have more than one product in clinical testing and trials at the same time. This news comes following the identification of two distinct parallel paths in developing pharmaceutical products for FDA approval. The first being the highly publicized H1N1 Swine flu and the deadly H1N5 Avian flu, and the second being a newly formed initiative for Veterans who suffer from Post Traumatic Stress Disorder (PTSD). Together with these initiatives, Cannabis Science is laying a solid foundation for entrance into the FDA and other government regulatory agencies for developing medicines for Influenza, PTSD and other ailments.
The Company looks forward to announcing its continued progress with these initiatives through the development of an online progress chart that will become available at the http://www.cannabisscience.com/ website in the near future. This online tracking initiative will allow the general public immediate access to monitor each stage of development, submit questions, and request special circumstance information as we take our cannabis-based drugs to market.
Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., stated, “Times are changing. There is an ever-increasing demand for our cannabis-based drugs, and this demand is growing exponentially throughout the United States and the rest of the world. Modern science supports the public demand for cannabis-based FDA approved drug products that reduce the impact of critical life altering illnesses. The public need for our products drives our efforts to rapidly move our drugs through all available regulatory channels. We believe this enormous public demand on a global scale is a major key to our success and we are very excited to be positioned to provide solutions. We are currently sourcing cGMP compliant facilities to produce our initial formulations for FDA compliant testing.
Veterans Post Traumatic Stress Disorder (PTSD) Program
We are rapidly moving forward with our program designed to test the efficacy of our cannabis extract-based oral medicine to provide immediate relief of the negative consequences of PTSD in our military veterans. A critical first step will be carried out by Dr. Mitch Earleywine (State University of New York (SUNY Albany, SAB) the first member of the Cannabis Science Scientific Advisory Board. He will conduct a Veterans survey regarding the use of medical marijuana for PTSD. The results of this survey will provide us with human data that we expect will assist in our efforts with the FDA and other governmental agencies to fast track our PTSD and our Flu project.
H1N1 Swine Flu & H1N5 Avian Flu
According to the CDC (http://www.cdc.gov/flu/avian/), the Avian flu (H5N1) has a 63%
Image via Wikipedia
mortality rate. Unfortunately, the Swine flu, while causing death at a much lower rate than the Avian flu, also appears to result in death via a similar mechanism. The common cause of death with these strains is organ failure, especially as seen in the lungs with the development of Adult Respiratory Distress Syndrome (ARDS). ARDS is caused by an excess immune-generated inflammatory response that leads to apoptosis (cell death) and subsequently to organ failure. The Company’s approach will mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry. Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances, and cardiovascular disease. Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.
http://biomedreports.com/articles/new-latest-news/5512-cannabis-science-reports-on-two-cannabis-based-drug-release-programs.html
__________________ hat tip to JCR ________________
Note: subsequent to Cannabis Science Inc ‘lozenge’ being contrued as targeted to children… (see ABC item discussed here)
Dr. Melamede notes, “psychoactive cannabinoids are in human mother’s milk. If God thinks it’s all right to use cannabinoids in an infant’s first food, who am I to disagree? We believe one of our formulations will prevent many deaths caused by H1N1 Swine Flu and H5N1 Avian Flu. If our formulation becomes an FDA approved drug and works in adults, we believe that all parents and their physicians should have the right to choose the best treatment for a child with a
potentially deadly illness. Public health officials have warned that H1N1 may be
comparable to the 1918 Influenza Pandemic that killed tens of millions globally
and hit young people especially hard. We are optimistic that the FDA has not and
will not be distracted by non-science-based hysteria and will treat cannabis-based medicines based on documented science as evidenced by its advancement of other cannabis-based medicines going through the FDA approval process now.”
Blair Anderson
http://mildgreens.blogspot.com/
Related articles by Zemanta
- Treatments for Swine and Bird Flu – Cannabis Science Inc. (mildgreens.blogspot.com)
- Obesity Emerges as Risk Factor in Severe Flu (nlm.nih.gov)
- Asthma Drugs Get ‘Precaution’ Labeling for Possible Psychiatric Side Effects (nlm.nih.gov)